What are the treatment options for Shy-Drager syndrome?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 17, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Research

Treatment for Shy-Drager syndrome focuses on managing symptoms, and the most effective approach typically includes a combination of medications and non-pharmacological interventions to address orthostatic hypotension, Parkinson's-like symptoms, and other related issues. The treatment options for Shy-Drager syndrome, now known as multiple system atrophy (MSA), are primarily aimed at alleviating symptoms and improving quality of life, as there is no cure for the condition.

Medications

Medications such as fludrocortisone (0.1-0.3 mg daily) or midodrine (2.5-10 mg three times daily) are often used to manage orthostatic hypotension, which is a common symptom causing dizziness upon standing 1. For Parkinson's-like symptoms, levodopa/carbidopa may be prescribed, starting at 25/100 mg three times daily, although the response is often limited 2. Urinary problems can be addressed with anticholinergics like oxybutynin (5 mg twice daily) or catheterization for retention.

Non-Pharmacological Approaches

Non-pharmacological approaches are equally crucial and include elevating the head of the bed 30 degrees at night, wearing compression stockings, increasing salt and fluid intake, and performing physical therapy to maintain mobility. Speech therapy can help with communication difficulties, while occupational therapy assists with daily activities. As the disease progresses, patients may require assistance with breathing (CPAP for sleep apnea) and swallowing.

Disease Progression and Management

Regular follow-up with neurologists specializing in movement disorders is essential, as treatment needs to be adjusted as symptoms evolve in this progressive neurodegenerative disorder that affects the autonomic nervous system and movement control 3, 4. The goal of treatment is to manage symptoms effectively, improve quality of life, and reduce morbidity and mortality associated with the condition.

Given the complexity and progressive nature of Shy-Drager syndrome, a comprehensive and multidisciplinary approach to care is necessary, incorporating both pharmacological and non-pharmacological interventions tailored to the individual patient's needs and symptom profile.

References

Research

Levodopa therapy for Parkinsonism in the Shy-Drager syndrome.

Journal of neurology, neurosurgery, and psychiatry, 1973

Research

[Shy-Drager syndrome: a rare cause of orthostatic hypotension].

Deutsche medizinische Wochenschrift (1946), 1999

Research

[A case report of Shy-Drager disease].

Neurologia i neurochirurgia polska, 1997

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.